OR Edge Morning Report | Issue 010 Tuesday, May 5, 2026 | 6:00 AM EST

Guiding Every Case to Certainty and Calm

Yetsenia Tyson, RN

Estimated Reading Time: 7 minutes

I was pulling gloves for a 7 AM case last week when I realized the brand had changed; no memo, no announcement, just a quieter, cheaper substitute because the original price spiked 100% overnight.

Not missing. Not recalled. Just different. A different brand than we had been using quietly swapped in at some point without announcement. The original had gotten too expensive to keep on the shelf.

Nobody made a big announcement. There was no memo. The supply chain just shifted beneath us, and we adjusted without realizing it was a symptom of something much larger.

That is how tariff pressure works inside a perioperative unit. It does not arrive with sirens. It arrives in a substituted product, a higher line item on a supply order, a vendor conversation your administrator is having right now that has not made it back to the floor yet.

If you run an independent ASC in 2026, that conversation is happening whether you are in it or not.

⚠️ TARIFF ALERT: Tariffs on rubber medical and surgical gloves are set to reach 100% in 2026, doubling from 50% in 2025. Read that again.

Medical supply chain costs are projected to rise 2.41% in 2026, driven by higher prices for surgical supplies, capital equipment, and IT services. That number sounds manageable in isolation. It is not manageable in context.

The United States imported over $75 billion in medical devices and supplies in 2024, and today, 70% of all medical devices marketed in the US are produced overseas. That means the items your OR runs on every single day, gloves, drapes, suction devices, cautery pencils, irrigation supplies, are manufactured in countries now subject to new and escalating import taxes.

The US imports 80 to 90% of its personal protective equipment (PPE), with 75% of PPE sourced from China. The tariff structure on those items is not stable.

82% of surveyed physicians expect tariff-related import expenses to increase hospital and health system costs by 15% within the next six months. Certain products, like enteral syringes, now face tariffs as high as 245%.

When a company the size of Johnson and Johnson projects $400 million in tariff costs and emphasizes very limited price leverage, it tells you everything about where the pressure ultimately lands: on the facilities buying the products.

Here is the part that matters most for the people reading this newsletter.

Large hospital systems have group purchasing contracts negotiated years in advance. They have dedicated supply chain teams. They have legal departments that review vendor agreements for tariff adjustment clauses. They have the volume to threaten a supplier conversation and mean it.

Independent ASCs have the relationships they have built and the margins they are working with.

For a South Florida ASC, a 15% increase in supply costs without a corresponding increase in facility fees can turn a profitable GI case into a break-even or losing proposition. Independent administrators often discover price hikes only after the invoice arrives. Large systems draw down buffer inventory when shipments pause. Independent ASCs feel the gap immediately.

Health systems are facing significant margin pressure in 2026 due to policy and regulatory changes, including reductions in Medicaid funding and the compounding impact of tariffs. Now remove the institutional buffers and apply that same pressure to an independent center operating on tighter cost controls. That is the reality inside most of the ASCs on this list right now.

One. Audit your top 20 supply line items against your last three orders.

Look for substitutions, price increases, or allocation flags. Your top 20 line items represent the highest spend and the highest disruption risk. If you cannot pull that report in under an hour, your inventory visibility is already at risk. This is not a future problem. This is a Tuesday morning problem.

Two. If you are not currently in a GPO (group purchasing organization), that conversation needs to happen this month.

The Healthcare Supply Chain Association reports GPOs reduce healthcare supply costs by 10 to 18% compared to prices facilities would negotiate independently. Independent ASCs that purchase alone are paying a premium that compounds every time a tariff increase hits a product category. A GPO does not solve everything, but it closes the negotiating gap between you and a system that buys at ten times your volume.

Three. Review your vendor contracts for tariff adjustment language.

Identify agreements with distributors and suppliers that lack tariff adjustment clauses and prioritize renegotiation of contracts that expire within the next 12 months. If your contracts are silent on tariff pass-through, your vendor has every right to invoice the increase directly to you with no notice. That is a budget conversation you do not want to have mid-quarter.

The supply chain conversation seldom starts in the administrator's office. It starts when a scrub tech quietly asks why the instrument kit looks different. It starts when a circulating nurse notices the glove dispenser has a new brand. It starts when the charge nurse pulls the weekly supply order, and something is on allocation again with no estimated return date.

By the time the cost increase makes it onto an invoice, the floor has already been living with the consequence for weeks.

The centers that manage this well are not the ones with the largest supply budgets. They are the ones where someone is paying attention at the point of use and where that information travels up to the administrator before the vendor does.

That communication loop is not a technology problem. It is a workflow problem. And it is solvable before the next order cycle.

The connection between global trade policy and a day-of-surgery cancellation at your independent ASC is not theoretical. It runs directly through your supply order, your par levels, and the vendor relationships you either have or do not have documented anywhere right now.

Everything I am describing, supply visibility, vendor relationships, and cost documentation, lives inside the same operational story that determines whether your independent ASC survives a consolidation conversation, wins a payer negotiation, or passes an accreditation review.

In the South Florida market, ASCs are either growing or being acquired. The centers that come out of 2026 intact are not the ones that react fastest to tariff news. They are the ones who already have their house documented before the pressure arrives.

If you are building that documentation now, comment. I want to know where you are in that process.

Supply Costs Are Rising Faster Than Your Facility Fee: Vizient's 2026 Spend Management Outlook projects medical and surgical supply inflation will reach 2.58% this year, with pharmaceutical costs rising at 3.35%. For independent ASCs without volume-based contract protections, these are not averages. They are floor-level minimums.

The Purchasing Power Gap Is Measurable: The Healthcare Supply Chain Association reports that GPOs (group purchasing organizations) reduce supply costs by 10 to 18% compared to independent purchasing. In a tariff environment, that gap is not a negotiating preference. It is a margin protection decision.

The Investigation Your Vendor Has Not Told You About: The Commerce Department's Section 232 investigation into imported medical equipment, PPE, and consumables launched in September 2025 and remains under review. A ruling could affect product categories your OR uses daily. Independent ASCs should be watching this before their next contract renewal conversation.

Free. No fluff. Written from the floor by a perioperative RN living the same reality you are every single day.

Pull your cancellation data this week. Reply and tell me what you find.

The tariff conversation is easy to file under "things that happen at the policy level and eventually trickle down."

Do not file it there.

What is happening to surgical supply costs right now is not trickling. It is arriving line item by line item on invoices that your purchasing team is absorbing quietly, so the OR keeps moving. The question is not whether your center is being affected. The question is whether you know exactly where and by how much.

Independent ASCs that document their cost exposure now will negotiate with clarity. The ones that wait will negotiate from surprise.

Clarity is always the better starting position.

The supply chain pressure in Issue 010 raises a question I hear from perioperative nurses and ASC administrators more often than any other right now: how do you retain the clinical staff that makes your independent center worth protecting in the first place?

Issue 011 will cover workforce retention at independent ASCs, what the data says about why perioperative nurses leave, what the centers keeping their teams intact are doing differently, and what it costs an independent ASC when a single experienced OR nurse walks out the door.

If you have a story from your own center, comment here before Monday. I want to hear from the floor before I write the research.

See you Tuesday at 6:00 AM EST.

With purpose,

Yetsenia Tyson, RN.

Founder and CEO.

Haleris OR Edge Morning Report

oredgemorningreport.com

All statistics were verified against live sources before publication. No statistic in the OR Edge Morning Report is published without a confirmed, accessible URL.

OR Edge Morning Report maintains a strict data integrity standard. We verify every statistic against its source before publication. If you identify a discrepancy, please reply directly to this email.